The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...
Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut ...
In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
GB Logistics Commerce IPO opened for subscription on January 24, attracting strong investor interest. The IPO aims to raise ₹25 crore, with shares priced between ₹95 and ₹102. Listing on BSE SME is ...
U.S. liquefied natural gas exporter Venture Global couldn’t have timed its initial public offering better: It comes just days ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback